TD Cowen initiated coverage of Kiniksa (KNSA) with a Buy rating and $60 price target The firm says Kiniksa is at a “pivotal stage” as Arcalyst’s launch continues to ramp while KPL-387 could offer more favorable dosing. This could extend the franchise and significantly improve the company’s earnings, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: